Kiromic BioPharma, Inc. (KRBP )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol KRBP
- Company Kiromic BioPharma, Inc.
- Price $1.17
- Changes Percentage 46.25
- Change 0.37
- Day Low $1
- Day High $1.17
- Year High $3.78
- Year Low $0.75
- Market Cap $1,808,726
- Price Avg 50 EMA (D) $0.93
- Price Avg 200 EMA (D) $1.72
- Exchange NASDAQ
- Volume 300
- Average Volume 1,563
- Open $1
- Previous Close $0.8
- EPS -6.22
- PE -0.19
- Earnings Announcement 2025-03-17 10:59:00
- Shares Outstanding $1,545,920
Company brief: KIROMIC BIOPHARMA, INC. (KRBP )
- Healthcare
- Biotechnology
- Mr. Pietro Bersani CPA, J.D.
- https://www.kiromic.com
- US
- N/A
- 10-16-2020
- US4976342042
Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.